Unknown

Dataset Information

0

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma.


ABSTRACT:

Introduction

Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose-schedule are debated. A lower dose-schedule than standard-dose bevacizumab (10 mg/kg 2-weekly) might offer similar benefits with lower costs. At our Institution, patients are randomly assigned at time of primary diagnosis to Neuro-Oncologists, who have varying practices in terms of bevacizumab dose-schedule upon progression.

Methods

In a retrospective analysis we examined overall survival (OS), measured from first administered bevacizumab dose until death, according to dose-schedule. Patients with de novo WHO Grade IV GBM who received standard- or reduced-dose (5 mg/kg 2-weekly) bevacizumab were included. MGMT methylation status and time from diagnosis to bevacizumab start were examined as prognostic variables. Clinical benefit and a comparative cost analysis were assessed.

Results

In total, 1127 bevacizumab doses were administered to 118 patients [Median: 7, Range: 1-44]. Median OS (mOS) was 5.8 months. 69 (59%) patients received standard-dose bevacizumab (mOS: 5.97 months) and 49 patients received reduced-dose (mOS: 5.7 months). No statistically significant difference in OS between dosing schedule was seen (HR: 1.11, P-value: .584). Patients with MGMT methylated tumors (43%) had improved OS compared to those with unmethylated tumors; 7.03 vs 4.97 months (HR: 0.61, P-value: .027). If all patients were treated with reduced-dose bevacizumab, an estimated €2.4M cost reduction would be observed.

Conclusions

In this retrospective study, reduced-dose bevacizumab schedule resulted in similar OS to standard-dose bevacizumab monotherapy with substantial cost savings. MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM.

SUBMITTER: Gleeson JP 

PROVIDER: S-EPMC6970030 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Introduction</h4>Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose-schedule are debated. A lower dose-schedule than standard-dose bevacizumab (10 mg/kg 2-weekly) might offer similar benefits with lower costs. At our Institution, patients are randomly assigned at time of primary diagnosis to Neuro-Oncologists, who have varying practices in terms of bevacizumab dose-schedule upon progression.<h4>Methods</h4>In a retrospective analysis we examin  ...[more]

Similar Datasets

| S-EPMC7229248 | biostudies-literature
| S-EPMC6656330 | biostudies-literature
| S-EPMC7310142 | biostudies-literature
| S-EPMC6007273 | biostudies-other
| S-EPMC4553035 | biostudies-literature
| S-EPMC7028458 | biostudies-literature
| S-EPMC5564655 | biostudies-other
| S-EPMC10114040 | biostudies-literature
| S-EPMC3122280 | biostudies-literature
| S-EPMC8032382 | biostudies-literature